Education
About Us
Working with TipRanks
Follow Us
Valneva SE (FR:VLA)
:VLA
VLA Stock Chart & Stats
€4.34
-€0.05(-2.40%)
At close: 4:00 PM EST
€4.34
-€0.05(-2.40%)
Day’s Range― - ―
52-Week Range€2.25 - €5.42
Previous CloseN/A
Volume233.04K
Average Volume (3M)1.29M
Market Cap
€746.52M
Enterprise Value€782.14M
Total Cash (Recent Filing)€161.31M
Total Debt (Recent Filing)€196.92M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding172,213,490
10 Day Avg. Volume925,642
30 Day Avg. Volume1,288,661
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.74
Price to Sales (P/S)1.86
P/FCF Ratio-3.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.70Price Target Upside77.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Stable Government-driven Vaccine Revenue (IXIARO Growth)Growth in IXIARO sales, driven by U.S. Department of Defense and European purchases, underscores a durable revenue stream from institutional contracts. Such government and defense demand provides revenue stability and predictable cash inflows while the company leverages existing commercial infrastructure.
Meaningful Clinical And Regulatory Progress Across PipelineNew marketing authorizations and completion of Phase III vaccinations materially derisk the pipeline, expanding addressable markets and shortening commercialization timelines. These milestones increase long-term commercial optionality and improve prospects for sustainable product revenues once approvals and rollouts advance.
Improved Near-term Financial Flexibility Via Refinancing And CashA stronger cash buffer and completed debt refinancing reduce short-term liquidity risk and extend runway to fund R&D and commercial launches. This enhanced flexibility supports execution of clinical programs and commercialization plans without immediate dilutive financing, improving strategic optionality.
Bears Say
Large Operating Loss And Negative Adjusted EBITDASizable operating losses and negative EBITDA indicate the business is not yet self-sustaining, forcing reliance on external financing or asset sales to fund operations. Persistent deficits can constrain R&D investment pacing and increase refinancing or dilution risk over the medium term.
Weak Cash Generation (negative Operating And Free Cash Flow)Negative operating and free cash flows reflect difficulty converting revenues into internal funding. Over several quarters this undermines liquidity resilience and increases dependence on capital markets or partnerships to finance clinical programs and commercialization, pressuring strategic execution.
High Leverage And Regulatory Uncertainty For Key AssetsElevated leverage limits balance-sheet flexibility if regulatory setbacks materialize. The U.S. IXCHIQ suspension and unclear regulatory/funding path for the Zika candidate create execution risk for key future revenue drivers, potentially delaying monetization while debt obligations remain.
Valneva News
VLA FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest stock price was €2.25 and its highest was €5.42 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €746.52M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Mar 19, 2026 which is in 30 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on Nov 20, 2025. The company reported -€0.217 earnings per share for the quarter, missing the consensus estimate of -€0.14 by -€0.077.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Undervalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.14.
How many shares outstanding does Valneva SE have?
Valneva SE has 172,213,490 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.217 in its last earnings report, missing expectations of -€0.14. Following the earnings report the stock price went up 0.91%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in FR:VLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
VLA Stock 12 Month Forecast
Average Price Target
€7.70
▲(77.42% Upside)
Technical Analysis
Options Prices
Currently, No data available
---